BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Alzheimer's disease
Artificial intelligence
Biosimilars
China CAR T
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Wednesday, April 24, 2024
Breaking News: Try BioWorld for free for two weeks
See today's BioWorld Science
Home
» DB-2306 demonstrates efficacy in models of autoimmune and inflammatory disease
X
Upgrade your daily dose of biopharma and medtech news
Subscribe to BioWorld™ news services
See subscription options
To read the full story,
subscribe
or
sign in
.
Inflammatory
DB-2306 demonstrates efficacy in models of autoimmune and inflammatory disease
Nov. 24, 2022
No Comments
A research team at Duality Biologics (Suzhou) Co. Ltd. has discovered a novel anti-TNF-α monoclonal antibody-drug conjugate (ADC), DB-2306, as a potential therapeutic candidate for the treatment of autoimmune disease.
BioWorld Science
Conferences
Inflammatory
Antibody-drug conjugate